Rheumatology

Antifibrotic

Questions discussed in this category

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?

Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?

6 Answers available

Papers discussed in this category

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Lancet Respir Med, 2021 Jan

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.

Related Topics in Rheumatology